Wednesday, September 24, 2025 3:07:16 PM
CTMX................................................https://stockcharts.com/h-sc/ui?s=CTMX&p=W&b=5&g=0&id=p86431144783
Recent CTMX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 10:41:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 10:35:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 10:25:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 10:21:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 08:05:37 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/18/2026 08:05:53 PM
- CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 03/18/2026 02:46:40 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/16/2026 08:37:02 PM
- CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 03/16/2026 08:04:55 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 03/16/2026 08:01:39 PM
- CytomX highlights clinical progress for lead cancer drug in Q4 update • IH Market News • 03/16/2026 03:36:20 PM
- CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/16/2026 11:05:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 11:04:08 AM
- CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer • GlobeNewswire Inc. • 03/16/2026 11:00:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 03/04/2026 08:18:13 PM
- CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026 • GlobeNewswire Inc. • 03/04/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:28:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:27:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:25:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:23:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:22:15 PM
- CytomX Therapeutics to Present at Upcoming February Conferences • GlobeNewswire Inc. • 02/04/2026 01:00:00 PM
- Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development • GlobeNewswire Inc. • 01/27/2026 12:00:00 PM
- CytomX Therapeutics Announces Business Update and Company Milestones for 2026 • GlobeNewswire Inc. • 01/08/2026 01:00:00 PM
- CytomX Therapeutics to Present at Upcoming December Investor Conferences • GlobeNewswire Inc. • 11/25/2025 01:00:00 PM
